Wouter R van Furth
Overview
Explore the profile of Wouter R van Furth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
1205
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Serioli S, Verstegen M, Kleijwegt M, Fiacchini G, van Furth W, Dallan I
Oper Neurosurg (Hagerstown)
. 2025 Mar;
PMID: 40042292
No abstract available.
2.
Kleijn T, Ameline B, Schreuder W, Szuhai K, Kooistra W, van Kempen L, et al.
Mod Pathol
. 2025 Jan;
38(6):100717.
PMID: 39863110
Fibro-osseous tumors of the craniofacial bones are a heterogeneous group of lesions comprising cemento-osseous dysplasia (COD), cemento-ossifying fibroma (COF), juvenile trabecular ossifying fibroma (JTOF), psammomatoid ossifying fibroma (PsOF), fibrous dysplasia...
3.
Nollen J, Brunsveld-Reinders A, Peul W, van Furth W
Br J Nurs
. 2024 Oct;
33(18):S4-S12.
PMID: 39392332
Background: Diabetes insipidus (DI) is a common complication following pituitary surgery, causing significant health issues if left untreated. As part of the diagnostic process, accurate urinary output monitoring via indwelling...
4.
van Trigt V, Bakker L, Pelsma I, Zandbergen I, Jentus M, Kruit M, et al.
J Clin Endocrinol Metab
. 2024 Sep;
PMID: 39292628
Purpose: To evaluate patients with prolactinoma treated surgically in a time when elective prolactinoma surgery became routine in our center, using a comprehensive outcome set, focusing on preoperative assessments, surgical...
5.
Miladinovic V, Klaver Y, Krol A, Kroesen M, Verbist B, Habraken S, et al.
Strahlenther Onkol
. 2024 Aug;
200(12):1066-1073.
PMID: 39207463
Background: Chordomas and chondrosarcomas of the skull base are rare, slowly growing malignant bone neoplasms. Despite their radioresistant properties, proton therapy has been successfully used as an adjunct to resection...
6.
van Trigt V, Bakker L, Lu H, Pelsma I, Verstegen M, van Furth W, et al.
Pituitary
. 2024 Jul;
27(5):614-624.
PMID: 39042164
Purpose: To assess the utility of [F]fluoroethyl-L-tyrosine PET co-registered with magnetic resonance imaging ([F]FET-PET/MRI) in patients with difficult-to-localize prolactinoma to inform clinical decision-making and (surgical) treatment planning. Methods: Retrospective cohort...
7.
Bakker L, Verstegen M, Manole D, Lu H, Decramer T, Pelsma I, et al.
Clin Endocrinol (Oxf)
. 2024 May;
101(2):142-152.
PMID: 38818709
Objective: To report our experience with F-fluoro-ethyl-tyrosine (FET) positron emission tomography-computed tomography (PET-CT) co-registered with magnetic resonance imaging (MRI) (FET-PET/MRI) in the care trajectory for persistent acromegaly. Design: Prospective case...
8.
Neuropsychiatric Adverse Effects of Synthetic Glucocorticoids: A Systematic Review and Meta-Analysis
Koning A, van der Meulen M, Schaap D, Satoer D, Vinkers C, van Rossum E, et al.
J Clin Endocrinol Metab
. 2023 Dec;
109(6):e1442-e1451.
PMID: 38038629
Context: Synthetic glucocorticoids are widely used to treat patients with a broad range of diseases. While efficacious, glucocorticoids can be accompanied by neuropsychiatric adverse effects. Objective: This systematic review and...
9.
van Trigt V, Zandbergen I, Pelsma I, Bakker L, Verstegen M, van Furth W, et al.
Pituitary
. 2023 Oct;
26(6):725-728.
PMID: 37897644
No abstract available.
10.
van Trigt V, Zandbergen I, Pelsma I, Bakker L, Verstegen M, van Furth W, et al.
Pituitary
. 2023 Sep;
26(5):611-621.
PMID: 37690076
Purpose: To describe care trajectories in patients with prolactinoma, aiming to clarify the rationale for surgery. Methods: Retrospective observational cohort study of consecutive patients with prolactinoma undergoing surgery from 2017...